News & Updates

The primary analysis of the phase III VAYHIT2 trial shows the treatment potential of ianalumab when combined with standard-of-care eltrombopag in individuals with primary immune thrombocytopenia (ITP) requiring second-line (2L) treatment after failure of first-line (1L) corticosteroids.

Treatment with benralizumab is associated with a significantly reduced risk of flares in patients with hypereosinophilic syndrome (HES) compared with placebo, according to the NATRON study presented at ASH 2025.

The LIVE-SMART trial presented at AASLD 2025 shows that lactulose and Tai chi may prevent falls in individuals with cirrhosis and portal hypertension.

Physical activity appears to pose transient risks of low back pain (LBP) flares but not functional limitations in the long term, according to a prospective, longitudinal case-crossover study.

Children with atopic dermatitis (AD) are at greater risk of impaired linear growth, but treatment with dupilumab may lessen the risk, suggests a study.

Outcomes are similar among patients with moderate-to-severe psoriasis who continued treatment with ustekinumab and those who switched to BAT2206, a drug being developed as a biosimilar of ustekinumab, according to a study.

Treatment with iGlarLixi* resulted in better clinical outcomes than IDegAsp** in Chinese adults with type 2 diabetes (T2D), regardless of age or disease duration at baseline, according to a post hoc analysis of the phase III Soli-D study presented at ATTD-ASIA 2025.